Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ChemDiv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Orionis Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by ChemDiv

    Menu

    ChemDiv

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ChemDiv

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials

              Details:

              ORB-011 is a cutting-edge attenuated, cis-targeted interferon immunotherapy compound. It is under phase 1 clinical development for the treatment of patients with advanced solid tumors.

              Lead Product(s): ORB-011

              Therapeutic Area: Oncology Product Name: ORB-011

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Orionis Biosciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ChemDiv

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ChemDiv Helps Advance Viriom's Influenza Treatment to Successful Phase I Clinical Trials Completion

              Details:

              AV5124 is an Influenza viral RNA processing inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of influenza.

              Lead Product(s): AV5124

              Therapeutic Area: Infections and Infectious Diseases Product Name: AV5124

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ChemDiv

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ChemDiv Created Unique KATO TM Platform for Development of Innovative Drugs Against Coronavirus Infection

              Details:

              Platform combines libraries of more than 120,000 unique potential antiviral molecules that targets various cellular proteins. Libraries cover highly important coronaviruses as well as HIV, HBV and Influenza.

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Avifavir

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 12, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY